DexCom, Inc. vs Rockwell Automation — how do they compare? DexCom, Inc. trades at $90.34 (market cap $33.79B), while Rockwell Automation trades at $450.39 (market cap $49.64B). The key difference: Rockwell Automation is the larger of the two by market cap, and Rockwell Automation pays a 1.23% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | ROK | |
|---|---|---|
Market Cap | $33.79B | $49.64B |
Sector | Health | Industrials |
52-Week High | $89.53 | $495.08 |
52-Week Low | $54.84 | $333.75 |
Enterprise Value | $33.24B | $52.77B |
Dividend Yield | — | 1.23% |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
Rockwell Automation (ROK) trades at $450.36, up 3.48% today, with a neutral technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $3.49, exceeding expectations, and raised full-year guidance amid robust demand in automation markets. Valuation ratios are elevated with a P/E of 41.85, but profitability remains solid with a net income margin of 13.38%.
Outlook is positive due to consistent earnings outperformance and AI-driven growth initiatives, though high valuation and inflationary cost pressures present risks. The consensus price target of $507.00 implies potential upside, supported by a majority analyst hold rating reflecting cautious optimism.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →